Augmentation of late sodium current unmasks the proarrhythmic effects of amiodarone

Cardiovascular Research

Volumn 77, Issue 3, 2008, Pages 481-488

  Wu, Lin ^a   Rajamani, Sridharan ^a   Shryock, John C ^a   Li, Hong ^a   Ruskin, Jeremy ^b   Antzelevitch, Charles ^c   Belardinelli, Luiz ^a  

^a CV THERAPEUTICS INC   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MASONIC MEDICAL RESEARCH LABORATORY   (United States)

Author keywords

Antiarrhythmic agents; Arrhythmia (mechanism); Ion channels; Long QT syndrome; Membrane potentials

Indexed keywords

AMIODARONE; POTASSIUM CHANNEL HERG; SEA ANEMONE TOXIN; SODIUM CHANNEL; SODIUM ION;

ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; DRUG MECHANISM; ELECTROCARDIOGRAPHY; EMBRYO CELL; EPICARDIUM; FEMALE; HEART BEAT; HEART PROARRHYTHMIA; HEART RATE VARIABILITY; HEART REPOLARIZATION; HUMAN; HUMAN CELL; ISOLATED HEART; KIDNEY CELL; MUSCLE ACTION POTENTIAL; NONHUMAN; PRIORITY JOURNAL; RABBIT; SODIUM CURRENT; TORSADE DES POINTES; UPREGULATION;

ACTION POTENTIALS; AMIODARONE; ANIMALS; ARRHYTHMIAS, CARDIAC; CNIDARIAN VENOMS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; HUMANS; LONG QT SYNDROME; MUSCLE PROTEINS; RABBITS; SODIUM CHANNELS;

EID: 38849186675     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvm069     Document Type: Article

References (36)

1. Connolly SJ. Evidence-based analysis of amiodarone efficacy and safety. Circulation 1999;100:2025-2034.
2. Nattel S, Singh BN. Evolution, mechanisms, and classification of antiarrhythmic drugs: focus on class III actions. Am J Cardiol 1999;84:11R-19R.
3. Connolly SJ. Meta-analysis of antiarrhythmic drug trials. Am J Cardiol 1999;84:90R-93R.
4. Kodama I, Kamiya K, Toyama J. Cellular electropharmacology of amiodarone. Cardiovasc Res 1997;35:13-29.
5. Lehtonen A, Fodstad H, Laitinen-Forsblom P, Toivonen L, Kontula K, Swan H. Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes. Heart Rhythm 2007;4:603-607.
6. Tomcsanyi J, Merkely B, Tenczer J, Papp L, Karlocai K. Early proarrhythmia during intravenous amiodarone treatment. Pacing Clin Electrophysiol 1999;22:968-970.
7. Bertholet M, Dubois C, Materne P, Demoulin JC, Kulbertus HE. Sudden marked QT prolongation after intravenous administration of amiodarone. Am J Cardiol 1983;52:1361.
8. Splawski I, Timothy KW, Tateyama M, Clancy CE, Malhotra A, Beggs AH et al. Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science 2002;297:1333-1336.
9. Makita N, Horie M, Nakamura T, Ai T, Sasaki K, Yokoi H et al. Drug-induced long-QT syndrome associated with a subclinical SCN5A mutation. Circulation 2002;106:1269-1274.
10. Belardinelli L, Shryock JC, Wu L, Song Y. Use of preclinical assays to predict risk of drug-induced torsades de pointes. Heart Rhythm 2005;2:S16-S22.
11. Roden DM. Long QT syndrome: reduced repolarization reserve and the genetic link. J Intern Med 2006;259:59-69.
12. Kannankeril PJ, Roden DM. Drug-induced long QT and torsade de pointes: recent advances. Curr Opin Cardiol 2007;22:39-43.
13. van Opstal JM, Schoenmakers M, Verduyn SC, de Groot SH, Leunissen JD, van Der Hulst FF et al. Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome. Circulation 2001;104:2722-2727.
14. Sicouri S, Moro S, Litovsky S, Elizari MV, Antzelevitch C. Chronic amiodarone reduces transmural dispersion of repolarization in the canine heart. J Cardiovasc Electrophysiol 1997;8:1269-1279.
15. Hondeghem LM, Lu HR, van Rossem K, De Clerck F. Detection of proarrhythmia in the female rabbit heart: blinded validation. J Cardiovasc Electrophysiol 2003;14:287-294.
16. Wu L, Shryock JC, Song Y, Belardinelli L. An increase in late sodium current potentiates the proarrhythmic activities of low-risk QT-prolonging drugs in female rabbit hearts. J Pharmacol Exp Ther 2006;316:718-726.
17. Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart 2006;92(Suppl. 4):iv6-iv14.
18. Thomsen MB, Verduyn SC, Stengl M, Beekman JD, de Pater G, van Opstal J et al. Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs. Circulation 2004;110:2453-2459.
19. Zhou Z, January CT. Both T- and L-type Ca2+ channels can contribute to excitation-contraction coupling in cardiac Purkinje cells. Biophys J 1998;74:1830-1839.
20. Rajamani S, Eckhardt LL, Valdivia CR, Klemens CA, Gillman BM, Anderson CL et al. Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. Br J Pharmacol 2006;149:481-489.
21. Singh BN, Wadhani N. Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs. J Cardiovasc Pharmacol Ther 2004;9(Suppl. 1):S85-S97.
22. Remme CA, Bezzina CR. Genetic modulation of cardiac repolarization reserve. Heart Rhythm 2007;4:608-610.
23. Raeder EA, Podrid PJ, Lown B. Side effects and complications of amiodarone therapy. Am Heart J 1985;109:975-983.
24. Antzelevitch C. Role of transmural dispersion of repolarization in the genesis of drug-induced torsades de pointes. Heart Rhythm 2005;2:S9-S15.
25. Yamaguchi M, Shimizu M, Ino H, Terai H, Uchiyama K, Oe K et al. T wave peak-to-end interval and QT dispersion in acquired long QT syndrome: a new index for arrhythmogenicity. Clin Sci (Lond) 2003;105:671-676.
26. Maltsev VA, Sabbah HN, Undrovinas AI. Late sodium current is a novel target for amiodarone: studies in failing human myocardium. J Mol Cell Cardiol 2001;33:923-932.
27. Kamiya K, Nishiyama A, Yasui K, Hojo M, Sanguinetti MC, Kodama I. Short-and long-term effects of amiodarone on the two components of cardiac delayed rectifier K(+) current. Circulation 2001;103:1317-1324.
28. Kohlhardt M, Fichtner H. Block of single cardiac Na+ channels by antiarrhythmic drugs: the effect of amiodarone, propafenone and diprafenone. J Membr Biol 1988;102:105-119.
29. Di Diego JM, Belardinelli L, Antzelevitch C. Cisapride-induced transmural dispersion of repolarization and torsade de pointes in the canine left ventricular wedge preparation during epicardial stimulation. Circulation 2003;108:1027-1033.
30. Undrovinas AI, Belardinelli L, Undrovinas NA, Sabbah HN. Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J Cardiovasc Electrophysiol 2006;17(Suppl. 1):S169-S177.
31. Maltsev VA, Undrovinas AI. Amulti-modal composition of the late Na+ current in human ventricular cardiomyocytes. Cardiovasc Res 2006;69:116-127.
32. Valdivia CR, Chu WW, Pu J, Foell JD, Haworth RA, Wolff MR et al. Increased late sodium current in myocytes from a canine heart failure model and from failing human heart. J Mol Cell Cardiol 2005;38:475-483.
33. Schrickel JW, Schwab JO, Yang A, Bitzen A, Luderitz B, Lewalter T. 'Torsade de pointes' in patients with structural heart disease and atrial fibrillation treated with amiodarone, beta-blockers, and digitalis. Pacing Clin Electrophysiol 2006;29:363-366.
34. Kijtawornrat A, Nishijima Y, Roche BM, Keene BW, Hamlin RL. Use of a failing rabbit heart as a model to predict torsadogenicity. Toxicol Sci 2006;93:205-212.
35. Hohnloser SH, Klingenheben T, Singh BN. Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia. Ann Intern Med 1994;121:529-535.
36. Yamashita N, Kaku T, Uchino T, Isomoto S, Yoshimatsu H, Ono K. Short-and long-term amiodarone treatments regulate Cav3.2 low-voltage-activated T-type Ca2+ channel through distinct mechanisms. Mol Pharmacol 2006;69:1684-1691.